<p>Cytek Biosciences, Inc. ((CTKB)) 举行了第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
<p>Cytek Biosciences, Inc. 最近的财报电话会议呈现出复杂的情绪，反映了成就与挑战。公司在亚太地区及其服务和试剂领域报告了显著的收入增长。然而，这些积极的发展被 EMEA 地区以及美国学术和政府部门的困难所抵消。此外，运营费用的增加和净亏损也对会议的整体情绪产生了影响。</p>
<h2>亚太地区的收入增长和经常性收入</h2>
<p>公司实现总收入为 5230 万美元，同比增长 2%。这一增长主要得益于亚太地区的强劲双位数增长以及经常性收入业务的持续势头，特别是在服务和试剂方面。</p>
<h2>亚太地区的强劲表现</h2>
<p>亚太地区（包括中国）在第三季度实现了 25% 的显著增长，得益于仪器、服务和试剂的增长。这一强劲表现凸显了该地区在 Cytek 整体收入增长中的关键作用。</p>
<h2>试剂收入增长</h2>
<p>全球范围内，试剂收入同比增长 21%，得益于运营改善，如更快的交货时间和增强的客户服务，这些都促进了这一强劲表现。</p>
<h2>服务收入增长</h2>
<p>服务收入表现强劲，第三季度同比增长 19%，突显了公司在这一领域的成功扩展。</p>
<h2>Aurora Evo 仪器发布</h2>
<p>Aurora Evo 分析仪的推出受到好评，为仪器收入增长做出了积极贡献，并增强了 Cytek 在市场上的创新优势。</p>
<h2>Cytek Cloud 用户基础扩展</h2>
<p>截至 2025 年 9 月 30 日，Cytek Cloud 拥有超过 22,600 名用户，自 2025 年初以来增长超过 40%，显示出强劲的采用率和用户参与度。</p>
<h2>EMEA 收入下降</h2>
<p>EMEA 地区经历了双位数的同比收入下降，主要由于对学术和政府客户的仪器销售显著减少，反映出区域挑战。</p>
<h2>美国学术和政府部门疲软</h2>
<p>在美国，仪器收入同比持平，学术和政府部门的需求因资金不确定性而受到压力。</p>
<h2>毛利率下降</h2>
<p>GAAP 毛利率从去年同期的 56% 下降至 53%，受到材料和关税成本上升以及间接费用增加的影响。</p>
<h2>运营费用增加</h2>
<p>第三季度运营费用上升至 3670 万美元，比 2024 年第三季度增长 10%，主要由于一般和行政费用的增加，包括与专利诉讼案件相关的法律费用。</p>
<h2>第三季度净亏损</h2>
<p>公司在第三季度报告净亏损 550 万美元，而去年同期净收入为 90 万美元，主要归因于运营损失增加和其他净收入减少。</p>
<h2>前瞻性指导</h2>
<p>Cytek Biosciences 在财报电话会议中提供了稳定的财务展望。公司重申 2025 年全年收入指导为 1.96 亿至 2.05 亿美元，强调服务和试剂的强劲势头以及美国仪器收入的稳定。亚太地区的增长和经常性收入流预计将继续推动公司的业绩。</p>
<p>总之，Cytek Biosciences 的财报电话会议突显了平衡的情绪，在收入增长方面取得了显著成就，特别是在亚太地区和经常性收入领域。然而，EMEA 地区和美国学术及政府部门的挑战，以及运营费用的增加和净亏损，提出了改进的空间。公司的前瞻性指导表明，展望稳定，仍有持续增长的潜力。</p>

CTKB

<p>Cytek Biosciences, Inc. 在其第三季度财报电话会议中报告了混合的业绩，总收入为 5230 万美元，同比增长 2%。增长主要得益于亚太地区 25% 的增长和全球试剂收入 21% 的增加。然而，EMEA 地区和美国学术部门的挑战导致净亏损为 550 万美元。运营费用上升了 10%，毛利率下降至 53%。公司重申了全年收入指导为 1.96 亿至 2.05 亿美元，尽管面临当前挑战，仍显示出稳定的增长潜力</p>

<p>Cytek Biosciences, Inc. ((CTKB)) has held its Q3 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Cytek Biosciences, Inc. ((CTKB)) 举行了第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
</div><p>The recent earnings call of Cytek Biosciences, Inc. presented a mixed sentiment, reflecting both achievements and challenges. The company reported significant revenue growth in the Asia Pacific (APAC) region and in its service and reagent sectors. However, these positive developments were counterbalanced by difficulties in the EMEA region and the U.S. academic and government sectors. Additionally, increased operating expenses and a net loss contributed to the overall balanced sentiment of the call.</p>
<div class="lb-trans"><p>Cytek Biosciences, Inc. 最近的财报电话会议呈现出复杂的情绪，反映了成就与挑战。公司在亚太地区及其服务和试剂领域报告了显著的收入增长。然而，这些积极的发展被 EMEA 地区以及美国学术和政府部门的困难所抵消。此外，运营费用的增加和净亏损也对会议的整体情绪产生了影响。</p>
</div><h2>Revenue Growth in APAC and Recurring Revenue</h2>
<div class="lb-trans"><h2>亚太地区的收入增长和经常性收入</h2>
</div><p>The company achieved a total revenue of $52.3 million, marking a 2% year-over-year increase. This growth was primarily driven by strong double-digit gains in the APAC region and sustained momentum in recurring revenue businesses, particularly in service and reagents.</p>
<div class="lb-trans"><p>公司实现总收入为 5230 万美元，同比增长 2%。这一增长主要得益于亚太地区的强劲双位数增长以及经常性收入业务的持续势头，特别是在服务和试剂方面。</p>
</div><h2>Strong Performance in APAC</h2>
<div class="lb-trans"><h2>亚太地区的强劲表现</h2>
</div><p>APAC, including China, saw a remarkable 25% increase in Q3, fueled by growth in instruments, service, and reagents. This robust performance underscores the region’s critical role in Cytek’s overall revenue growth.</p>
<div class="lb-trans"><p>亚太地区（包括中国）在第三季度实现了 25% 的显著增长，得益于仪器、服务和试剂的增长。这一强劲表现凸显了该地区在 Cytek 整体收入增长中的关键作用。</p>
</div><h2>Reagent Revenue Growth</h2>
<div class="lb-trans"><h2>试剂收入增长</h2>
</div><p>Globally, reagent revenue grew by 21% year-over-year, supported by operational improvements such as faster delivery times and enhanced customer service, which have contributed to this strong performance.</p>
<div class="lb-trans"><p>全球范围内，试剂收入同比增长 21%，得益于运营改善，如更快的交货时间和增强的客户服务，这些都促进了这一强劲表现。</p>
</div><h2>Service Revenue Growth</h2>
<div class="lb-trans"><h2>服务收入增长</h2>
</div><p>Service revenue demonstrated strong growth with a 19% increase in Q3 compared to the prior year quarter, highlighting the company’s successful expansion in this segment.</p>
<div class="lb-trans"><p>服务收入表现强劲，第三季度同比增长 19%，突显了公司在这一领域的成功扩展。</p>
</div><h2>Aurora Evo Instrument Launch</h2>
<div class="lb-trans"><h2>Aurora Evo 仪器发布</h2>
</div><p>The introduction of the Aurora Evo Analyzer was well-received, contributing positively to instrument revenue growth and reinforcing Cytek’s innovative edge in the market.</p>
<div class="lb-trans"><p>Aurora Evo 分析仪的推出受到好评，为仪器收入增长做出了积极贡献，并增强了 Cytek 在市场上的创新优势。</p>
</div><h2>Expansion of Cytek Cloud User Base</h2>
<div class="lb-trans"><h2>Cytek Cloud 用户基础扩展</h2>
</div><p>As of September 30, 2025, Cytek Cloud had over 22,600 users, representing a growth of more than 40% since the beginning of 2025, indicating strong adoption and user engagement.</p>
<div class="lb-trans"><p>截至 2025 年 9 月 30 日，Cytek Cloud 拥有超过 22,600 名用户，自 2025 年初以来增长超过 40%，显示出强劲的采用率和用户参与度。</p>
</div><h2>Decline in EMEA Revenue</h2>
<div class="lb-trans"><h2>EMEA 收入下降</h2>
</div><p>The EMEA region experienced a double-digit year-over-year revenue decline, primarily due to significantly reduced instrument sales to academic and government customers, reflecting regional challenges.</p>
<div class="lb-trans"><p>EMEA 地区经历了双位数的同比收入下降，主要由于对学术和政府客户的仪器销售显著减少，反映出区域挑战。</p>
</div><h2>U.S. Academic and Government Sector Weakness</h2>
<div class="lb-trans"><h2>美国学术和政府部门疲软</h2>
</div><p>In the U.S., instrument revenue remained flat year-over-year, with demand from academic and government sectors under pressure due to funding uncertainties.</p>
<div class="lb-trans"><p>在美国，仪器收入同比持平，学术和政府部门的需求因资金不确定性而受到压力。</p>
</div><h2>Lower Gross Profit Margin</h2>
<div class="lb-trans"><h2>毛利率下降</h2>
</div><p>The GAAP gross profit margin decreased to 53% from 56% in the prior year quarter, impacted by higher materials and tariff costs, as well as increased overhead.</p>
<div class="lb-trans"><p>GAAP 毛利率从去年同期的 56% 下降至 53%，受到材料和关税成本上升以及间接费用增加的影响。</p>
</div><h2>Increased Operating Expenses</h2>
<div class="lb-trans"><h2>运营费用增加</h2>
</div><p>Operating expenses rose to $36.7 million in Q3, up 10% from Q3 2024, driven by higher general and administrative expenses, including legal costs related to a patent litigation case.</p>
<div class="lb-trans"><p>第三季度运营费用上升至 3670 万美元，比 2024 年第三季度增长 10%，主要由于一般和行政费用的增加，包括与专利诉讼案件相关的法律费用。</p>
</div><h2>Net Loss in Q3</h2>
<div class="lb-trans"><h2>第三季度净亏损</h2>
</div><p>The company reported a net loss of $5.5 million in Q3, compared to a net income of $0.9 million in the previous year quarter, attributed to higher operational losses and lower net other income.</p>
<div class="lb-trans"><p>公司在第三季度报告净亏损 550 万美元，而去年同期净收入为 90 万美元，主要归因于运营损失增加和其他净收入减少。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Cytek Biosciences provided a stable financial outlook during the earnings call. The company reaffirmed its full-year 2025 revenue guidance of $196 million to $205 million, highlighting strong momentum in service and reagents and stabilization in U.S. instrument revenues. The growth in the APAC region and recurring revenue streams are expected to continue driving the company’s performance.</p>
<div class="lb-trans"><p>Cytek Biosciences 在财报电话会议中提供了稳定的财务展望。公司重申 2025 年全年收入指导为 1.96 亿至 2.05 亿美元，强调服务和试剂的强劲势头以及美国仪器收入的稳定。亚太地区的增长和经常性收入流预计将继续推动公司的业绩。</p>
</div><p>In conclusion, Cytek Biosciences’ earnings call highlighted a balanced sentiment with notable achievements in revenue growth, particularly in the APAC region and recurring revenue sectors. However, challenges in the EMEA region and U.S. academic and government sectors, along with increased operating expenses and a net loss, present areas for improvement. The company’s forward-looking guidance suggests a stable outlook with continued growth potential.</p>
<div class="lb-trans"><p>总之，Cytek Biosciences 的财报电话会议突显了平衡的情绪，在收入增长方面取得了显著成就，特别是在亚太地区和经常性收入领域。然而，EMEA 地区和美国学术及政府部门的挑战，以及运营费用的增加和净亏损，提出了改进的空间。公司的前瞻性指导表明，展望稳定，仍有持续增长的潜力。</p>
</div>

Cytek Biosciences 财报电话会议：情绪喜忧参半与增长